


IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1-15 (cancelled).


16 (currently amended). ~~Combination A combination~~ preparation ~~for the treatment of depression,~~ comprising (a) a compound ~~according to one of claims 1 to 9~~ having the formula



wherein

n is a number from 1 to 5;


R2 is OA, and R3 and R4 are each independently selected from H and OA, where A is H, C₁₋₃ alkyl or a group



where R6 and R7 are each independently alkyl or aryl;

R5 is C₁₋₃ alkyl;

R1 is a group




where X is S, O or NH;

or a racemate or pure (R)- or (S)-enantiomer thereof, or a physiologically acceptable salt thereof; and (b) at least one [[a]] further active ingredient selected from the group consisting of antidepressants, antipsychotics, sedatives, anxiolytics [[or]] and anti-migraine agents.

17 (currently amended). ~~Method for the treatment of A method for treating~~ depression in a mammal, comprising ~~the administration of~~ administering to the mammal a

therapeutically effective amount of a compound [[of]] having the formula I, as defined in claims 1 to 9, to said mammal




wherein

n is a number from 1 to 5;

R2 is OA, and R3 and R4 are each independently selected from H and OA, where A


is H, C₁₋₃ alkyl or a group



where R6 and R7 are each independently alkyl or aryl;

R5 is C₁₋₃ alkyl;

R1 is a group




where X is S, O or NH;

or a racemate or pure (R)- or (S)-enantiomer thereof, or a physiologically acceptable salt thereof.

18 (new). The method of Claim 17, wherein, in the formula for said compound, R3 and R4 are both H.

19 (new). The method of Claim 17, wherein, in the formula for said compound, A is H or a group



where R6 is C₁₋₁₂ alkyl, phenyl or methoxyphenyl.

20 (new). The method of Claim 17, wherein, in the formula for said compound, n is a number from 1 to 3 and R5 is C₃ alkyl.

- 21 (new). The method of Claim 17, wherein, in the formula for said compound, X is S.
- 22 (new). The method of Claim 21, wherein, in the formula for said compound, R1 is a 2-thienyl group.
- 23 (new). The method of Claim 17, wherein the compound is 5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol.
- 24 (new). The method of Claim 17, wherein the mammal is human.
- 25 (new). The method of Claim 24, wherein the depression is an endogenous depression or an organic depression not associated with Parkinson's disease.
- 26 (new). The method of Claim 24, wherein the depression is a unipolar depression (major depression) or a depressive phase of a manic-depressive disorder.
- 27 (new). The method of Claim 24, wherein the depression is an organic depression not associated with Parkinson's disease.
- 28 (new). The method of Claim 24, wherein the depression is an organic depression associated with Parkinson's disease.
- 29 (new). The method of Claim 28, wherein co-medication with another antidepressant is absent.
- 30 (new). The method of Claim 24, wherein the compound, or racemate or enantiomer thereof, or salt thereof, is administered parenterally, transdermally or mucosally.
- 31 (new). The method of Claim 24, wherein the compound, or racemate or enantiomer thereof, or salt thereof, is formulated as an ointment, paste, spray, film, plaster or iontophoretic device for transdermal administration.
- 32 (new). The method of Claim 24, wherein the active ingredient is administered transdermally via a plaster having the active ingredient in a matrix comprising an adhesive polymer.
- 33 (new). The method of Claim 24, wherein the active ingredient is administered transdermally and wherein a substantially constant plasma level of the active ingredient is established.
- 34 (new). The method of Claim 24, wherein the compound, or racemate or enantiomer thereof, or salt thereof, is administered in a dose of 0.5 to 50 mg per day.

35 (new). The method of Claim 17, further comprising administering to the mammal an additional active ingredient selected from the group consisting of antidepressants, antipsychotics, sedatives, anxiolytics and anti-migraine agents.

36 (new). The combination preparation of Claim 16, wherein the additional active ingredient is an antidepressant selected from the group consisting of selective serotonin reuptake inhibitors, mixed serotonin and noradrenaline reuptake inhibitors, selective noradrenaline reuptake inhibitors, monoamine oxidase inhibitors, alpha2 receptor and/or serotonin receptor modulators, adenosine antagonists, sigma-opioid receptor ligands, NK antagonists, melatonin antagonists and modulators of the hypothalamus-hypophysis-adrenal axis.